-+ 0.00%
-+ 0.00%
-+ 0.00%

Genfit to launch Phase 2a nangibotide proof-of-concept trial in ACLF in Q4 2026

PUBT·09/14/2026 16:15:25
Listen to the news
Genfit to launch Phase 2a nangibotide proof-of-concept trial in ACLF in Q4 2026
  • Genfit will start a Phase 2a proof-of-concept study of nangibotide in acute-on-chronic liver failure in Q4 2026.
  • Results will be presented in the future, with a data readout targeted in 2027.
  • The move follows Genfit’s summer 2026 acquisition of nangibotide, adding a late-stage asset to its liver-disease pipeline.
  • Prior mid-stage studies in septic shock and COVID-19 showed signals of improved survival and organ-function recovery, supporting the ACLF program.
  • Management framed ACLF as a high unmet-need indication, positioning the trial as a strategic pipeline expansion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609141215PRIMZONEFULLFEED1001262669) on September 14, 2026, and is solely responsible for the information contained therein.